Pulmonary Vein Isolation Outcomes With Fish Oils (PUFA)

Expanded access is temporarily not available for this treatment.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:
NCT00841451
First received: February 10, 2009
Last updated: April 3, 2014
Last verified: June 2011

February 10, 2009
April 3, 2014
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00841451 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulmonary Vein Isolation Outcomes With Fish Oils
Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)

Fish oil therapy may decrease the incidence of cardiac arrhythmias. This study will test whether pre-treatment with fish oils before catheter ablation of atrial fibrillation decreases the early post operative occurrence of atrial fibrillation.

Not Provided
Expanded Access
Not Provided
Not Provided
Atrial Fibrillation
Drug: Lovaza (Fish Oils)
Double blinded placebo controlled
Other Names:
  • Lovaza NDA021654
  • Omacor NDA021853
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Temporarily not available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Paroxysmal Atrial fibrillation (PAF).
  • Persistent atrial fibrillation. Persistent AF is not self-limited.

Exclusion Criteria:

  • Previous pulmonary vein isolation ablation procedure
  • Contraindication for anticoagulation
  • Permanent AF
  • Severe valvular pathology
  • Concurrent use of antiarrhythmic medications
  • Inability to give consent
  • Pregnancy
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00841451
06-123
Not Provided
St. Luke's-Roosevelt Hospital Center
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline
Principal Investigator: Suneet Mittal, MD St. Luke's-Roosevelt Hospital Center
St. Luke's-Roosevelt Hospital Center
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP